Two pancreatic cancer trials will read out this quarter, but after a string of failures with the project they look like a long shot.

After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.

Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.

One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.

The company's comparison of its ADCs to Enhertu seems farfetched.

Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.

When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.

Fuelled with a $500m Summit windfall Akeso advances its lead bispecific.

The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.